TAS-108
TAS-108
TAS-108 (pronunciation: T-A-S-One-Zero-Eight), also known as Sorafenib Tosylate, is a type of antineoplastic agent used in the treatment of certain types of cancer.
Etymology
The term TAS-108 is derived from the initials of the pharmaceutical company that developed it, Taiho Pharmaceutical Co., Ltd., and the number 108, which is the specific identifier for this drug within the company's product line.
Usage
TAS-108 is primarily used in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer, and renal cell carcinoma (RCC), a type of kidney cancer. It works by inhibiting the actions of certain proteins that promote the growth of cancer cells.
Related Terms
- Antineoplastic agent: A substance that inhibits the growth and spread of cancerous or potentially cancerous cells.
- Hepatocellular carcinoma (HCC): A type of liver cancer that starts in the hepatocytes, the main type of liver cell.
- Renal cell carcinoma (RCC): A type of kidney cancer that starts in the lining of the proximal convoluted tubule, a part of the small tubes in the kidney that transport waste molecules from the blood to the urine.
See Also
External links
- Medical encyclopedia article on TAS-108
- Wikipedia's article - TAS-108
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski